When was Timberlyne founded?

Timberlyne was founded in 2024 and raised its 1st funding round 1 year after it was founded.

Where is Timberlyne located?

Timberlyne is headquartered in San Diego, United States.

Is Timberlyne a funded company?

Timberlyne is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jan 09, 2025.

When was the latest funding round of Timberlyne?

Timberlyne's latest funding was a $***** Series A round on Jan 09, 2025, with participation from 6 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $3.93B in funding in 2026 to date.

Where does Timberlyne rank among its competitors?

Timberlyne ranks 138th amongst 309 active competitors, of which 122 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Timberlyne?

Timberlyne's top competitors include Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Timberlyne - 2026 Company Profile, Funding & Competitors

Timberlyne is a series A company based in San Diego (United States), founded in 2024. It operates as a Developer of therapeutics for autoimmune diseases. Timberlyne has raised $180M in funding from Abingworth. The company has 309 active competitors, including 122 funded and 69 that have exited. Its top competitors include companies like Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics.

Company Details

Developer of therapeutics for autoimmune diseases. It offers a lead program CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38 for the treatment of Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma.

Website: timberlyne-tx.com
Email ID: *****@timberlyne-tx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2024

Location

San Diego, United States

Stage

Series A

Total Funding

$180M in 1 round

Latest Funding Round

Series A, Jan 09, 2025, $*****

Investors

Abingworth & 5 more

Ranked

138^th among 309 active competitors

Similar Companies

Sana Biotechnology & 336 more

View Timberlyne's full profile

Timberlyne has raised a total funding of $180M over 1 round. Its latest funding round was a Series A round on Jan 09, 2025 for $*****. 6 investors participated in its latest round. Timberlyne has 6 institutional investors.

Here is the list of recent funding rounds of Timberlyne:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 09, 2025	4165250	Series A	2543221	5129950	7087482	3836010

Access funding benchmarks and valuations. Sign up today!

View details of Timberlyne's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Timberlyne include Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics. Here is the list of Top 10 competitors of Timberlyne, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
2nd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
3rd	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100
4th	Autolus 2015, London (United Kingdom), Public	Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases	$181M	Syncona, Nextech Invest & 7 others	65/100
5th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	65/100
6th	Sonoma Biotherapeutics 2012, San Francisco (United States), Series B	Developer of T-cell-based therapies for autoimmune and degenerative diseases	$335M	Lilly Asia Ventures, 8VC & 20 others	64/100
7th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
8th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	VenBio, Redmile Group & 10 others	64/100
9th	Alumis 2003, San Francisco (United States), Public	Developer of therapeutics for the treatment of auto-immune disease	$529M	Foresite Capital, VenBio & 15 others	63/100
10th	Jasper Therapeutics 1999, Redwood City (United States), Series A	Developer of therapeutics for chronic diseases by targeting mast cells and stem cells	$50M	Abingworth, Qiming & 7 others	63/100
138th	Timberlyne 2024, San Diego (United States), Series A	Developer of therapeutics for autoimmune diseases	$180M	Bain Capital Life Sciences, Abingworth & 4 others	37/100